About the Authors
- Niklas Bergvall
-
* E-mail: niklas.bergvall@novartis.com
Affiliation Novartis Pharma AG, Basel, Switzerland
- Charles Makin
-
Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America
- Raquel Lahoz
-
Affiliation Novartis Pharma AG, Basel, Switzerland
- Neetu Agashivala
-
Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America
- Ashish Pradhan
-
Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America
- Gorana Capkun
-
Affiliation Novartis Pharma AG, Basel, Switzerland
- Allison A. Petrilla
-
Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America
- Swapna U. Karkare
-
Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America
- Catherine Balderston McGuiness
-
Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America
- Jonathan R. Korn
-
Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America
Competing Interests
The authors have the following interests: The analyses for this study were funded by Novartis Pharma AG, the employer of NB, RL, NA, AP and GC. The following authors have a share in Novartis: NB, RL, NA, AP and GC. Fingolimod is a Novartis product. CM, AAP, SUK, CBM and JRK are employed by IMS Health. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: NB CM RL NA AP GC AAP SUK CBM JRK. Analyzed the data: NB CM AAP SUK CBM JRK. Contributed reagents/materials/analysis tools: NB CM RL AAP SUK CBM JRK. Wrote the paper: NB CM RL NA AP GC AAP SUK CBM JRK. Reviewed the paper: NB CM RL NA AP GC AAP SUK CBM JRK. Interpreted results: NB CM RL NA AP GC AAP SUK CBM JRK.